Ultragenyx Pharmaceutical(RARE) - 2024 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 60 Leveroni Court Novato, California 94949 (Address of principal executive offices) (Zip Code) (415) 483-8800 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...